As of 2025-10-30, the Fair Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -2.86 CAD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 7.83 CAD, the upside of Eupraxia Pharmaceuticals Inc is -136.54%.
With the market price of 7.83 CAD and our fair value calculation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is not a good investment. Investing in EPRX.TO stocks now will result in a potential loss of 136.54%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -4.00 | -22.99 | -23.26 | -28.22 | -25.50 | -20.79 |
| YoY growth | 44.29% | -474.75% | -1.17% | -21.33% | 9.63% | -88.67% |
| Market Cap (mil) | 396.20 |
| P/E | |
| Forward P/E |
| EPS | -0.57 |
| Avg earnings growth rate | -88.67% |
| TTM earnings | -28.96 |